ZLAB Stock Analysis: Zai Lab | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.071m USD | 12M Return: 12.5% | US98887Q1040 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.7M
Qual. Beats: 2
Rev. Trend: 90.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Zai Lab Limited is a Shanghai- and Pudong-based biopharmaceutical company that discovers, develops, and commercializes therapies in oncology, immunology, neuroscience, and infectious diseases. Founded in 2013 and listed on NASDAQ in 2017, the company generates revenue through a portfolio of commercialized drugs-including Zejula, VYVGART, NUZYRA, Optune, Qinlock, Xacduro, and Augtyro-spanning ovarian cancer, myasthenia gravis, bacterial infections, glioblastoma, gastrointestinal stromal tumors, and non-small cell lung cancer.
Its business model combines in-licensed products from global partners with internal R&D, supported by a network of strategic collaborations with Tesaro, NovoCure, Deciphera Pharmaceuticals, Paratek, argenx, Turning Point Therapeutics, Entasis Therapeutics, Karuna Therapeutics, Pfizer, Amgen, and Boehringer Ingelheim. Such licensing and co-development agreements are a common structure for China-based biotechs, which typically leverage in-licensed late-stage assets to accelerate commercialization domestically while developing their own pipeline for global markets.
- VYVGART launch in China drives immunology segment revenue growth
- NRDL price negotiations pressure margins on Zejula and portfolio drugs
- Pipeline catalysts from Pfizer and Amgen collaborations expand oncology and immunology pipeline
| Net Income: -198.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -0.24 > 1.0 |
| NWC/Revenue: 99.64% < 20% (prev 152.4%; Δ -52.79% < -1%) |
| CFO/TA -0.16 > 3% & CFO -159.2m > Net Income -198.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.3m) vs 12m ago 1.94% < -2% |
| Gross Margin: 54.69% > 18% (prev 61.32%; Δ -6.62% > 0.5%) |
| Asset Turnover: 40.47% > 50% (prev 38.11%; Δ 2.37% > 0%) |
| Interest Coverage Ratio: -31.91 > 6 (EBIT TTM -196.6m / Interest Expense TTM 6.16m) |
| A: 0.43 (Total Current Assets 864.4m - Total Current Liabilities 424.2m) / Total Assets 1.02b |
| B: -2.71 (Retained Earnings -2.78b / Total Assets 1.02b) |
| C: -0.18 (EBIT TTM -196.6m / Avg Total Assets 1.09b) |
| D: 1.22 (Book Value of Equity 563.3m / Total Liabilities 460.6m) |
| Altman-Z'' = -5.95 = D |
| DSRI: 0.72 (Receivables 75.4m/105.0m, Revenue 441.7m/441.6m) |
| GMI: 1.12 (GM 61.32% / 54.69%) |
| AQI: 1.82 (AQ_t 0.10 / AQ_t-1 0.05) |
| SGI: 1.00 (Revenue 441.7m / 441.6m) |
| TATA: -0.04 (NI -198.4m - CFO -159.2m) / TA 1.02b) |
| Beneish M = -2.67 (Cap -4..+1) = A |
As of November 18, 2026, the stock is trading at USD 23.53 with a total of 690,592 shares traded. Over the past week, the price has changed by -10.97%, over one month by -2.20%, over three months by -8.23% and over the past year by +12.48%.
Current recommended Stop Loss: 19.90 (which is 15.4% or 2.4 ATR below the current price).
Zai Lab has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ZLAB.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.1 | 45% |
P/S = 6.9526
P/B = 5.7692
Revenue TTM = 441.7m USD
EBIT TTM = -196.6m USD
EBITDA TTM = -180.2m USD
Long Term Debt = 9.56m USD (estimated: total debt 267.4m - short term 257.9m)
Short Term Debt = 257.9m USD (from shortTermDebt, last quarter)
Debt = 282.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.1m
Net Debt = -277.1m USD (calculated: Debt 282.5m - CCE 559.7m)
Enterprise Value = 2.79b USD (3.07b + Debt 282.5m - CCE 559.7m)
Interest Coverage Ratio = -31.91 (Ebit TTM -196.6m / Interest Expense TTM 6.16m)
EV/FCF = -15.09x (Enterprise Value 2.79b / FCF TTM -185.2m)
FCF Yield = -6.63% (FCF TTM -185.2m / Enterprise Value 2.79b)
FCF Margin = -41.93% (FCF TTM -185.2m / Revenue TTM 441.7m)
Net Margin = -44.91% (Net Income TTM -198.4m / Revenue TTM 441.7m)
Gross Margin = 54.69% ((Revenue TTM 441.7m - Cost of Revenue TTM 200.1m) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 54.70%)
Tobins Q-Ratio = 2.73 (Enterprise Value 2.79b / Total Assets 1.02b)
Interest Expense / Debt = 2.18% (Interest Expense 6.16m / Debt 282.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -155.3m (EBIT -196.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 864.4m / Total Current Liabilities 424.2m)
Debt / Equity = 0.50 (Debt 282.5m / totalStockholderEquity, last quarter 563.3m)
Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -277.1m / EBITDA -180.2m)
Debt / FCF = 1.50 (negative FCF - burning cash) (Net Debt -277.1m / FCF TTM -185.2m)
Total Stockholder Equity = 636.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.18% (Net Income -198.4m / Total Assets 1.02b)
RoE = -31.15% (Net Income TTM -198.4m / Total Stockholder Equity 636.9m)
RoCE = -30.41% (EBIT -196.6m / Capital Employed (Equity 636.9m + L.T.Debt 9.56m))
RoIC = -18.59% (negative operating profit) (NOPAT -155.3m / Invested Capital 835.5m)
WACC = 7.63% (E(3.07b)/V(3.35b) * Re(8.17%) + D(282.5m)/V(3.35b) * Rd(2.18%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.14 | Cagr: -61.74%
[DCF] Fair Price = unknown (Cash Flow -185.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.99 | # QB: 2
Revenue Correlation: 90.18 | Revenue CAGR: 20.71% | SUE: 0.03 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.43 | Chg30d=+17.92% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.88 | Chg30d=+14.55% | Revisions=+17% | GrowthEPS=-17.3% | GrowthRev=-4.6%
EPS next Year (2027-12-31): EPS=-1.98 | Chg30d=+6.04% | Revisions=+17% | GrowthEPS=-5.7% | GrowthRev=+22.4%
[Analyst] Revisions Ratio: +30% (up=5, down=2)